Retinal Vein Occlusion Treatment Market (By Disease Type: Central Retinal Vein Occlusion, Branch Retinal Vein Occlusion; By Treatment Type; By End-user) - Global Industry Analysis, Size, Share, Growth, Trends, Revenue, Regional Outlook and Forecast 2022-2030

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Retinal Vein Occlusion Treatment Market 

5.1. COVID-19 Landscape: Retinal Vein Occlusion Treatment Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Retinal Vein Occlusion Treatment Market, By Disease Type

8.1. Retinal Vein Occlusion Treatment Market, by Disease Type, 2022-2030

8.1.1 Central Retinal Vein Occlusion (CRVO)

8.1.1.1. Market Revenue and Forecast (2017-2030)

8.1.2. Branch Retinal Vein Occlusion (BRVO)

8.1.2.1. Market Revenue and Forecast (2017-2030)

Chapter 9. Global Retinal Vein Occlusion Treatment Market, By Treatment

9.1. Retinal Vein Occlusion Treatment Market, by Treatment, 2022-2030

9.1.1. Anti-vascular Endothelial Growth Factor (Anti-VEGF)

9.1.1.1. Market Revenue and Forecast (2017-2030)

9.1.2. Corticosteroid Drugs

9.1.2.1. Market Revenue and Forecast (2017-2030)

9.1.3. Others

9.1.3.1. Market Revenue and Forecast (2017-2030)

Chapter 10. Global Retinal Vein Occlusion Treatment Market, By End-user 

10.1. Retinal Vein Occlusion Treatment Market, by End-user, 2022-2030

10.1.1. Hospital & Clinics

10.1.1.1. Market Revenue and Forecast (2017-2030)

10.1.2. Research and Academics

10.1.2.1. Market Revenue and Forecast (2017-2030)

10.1.3. Others

10.1.3.1. Market Revenue and Forecast (2017-2030)

Chapter 11. Global Retinal Vein Occlusion Treatment Market, Regional Estimates and Trend Forecast

11.1. North America

11.1.1. Market Revenue and Forecast, by Disease Type (2017-2030)

11.1.2. Market Revenue and Forecast, by Treatment (2017-2030)

11.1.3. Market Revenue and Forecast, by End-user (2017-2030)

11.1.4. U.S.

11.1.4.1. Market Revenue and Forecast, by Disease Type (2017-2030)

11.1.4.2. Market Revenue and Forecast, by Treatment (2017-2030)

11.1.4.3. Market Revenue and Forecast, by End-user (2017-2030)

11.1.5. Rest of North America

11.1.5.1. Market Revenue and Forecast, by Disease Type (2017-2030)

11.1.5.2. Market Revenue and Forecast, by Treatment (2017-2030)

11.1.5.3. Market Revenue and Forecast, by End-user (2017-2030)

11.2. Europe

11.2.1. Market Revenue and Forecast, by Disease Type (2017-2030)

11.2.2. Market Revenue and Forecast, by Treatment (2017-2030)

11.2.3. Market Revenue and Forecast, by End-user (2017-2030)

11.2.4. UK

11.2.4.1. Market Revenue and Forecast, by Disease Type (2017-2030)

11.2.4.2. Market Revenue and Forecast, by Treatment (2017-2030)

11.2.4.3. Market Revenue and Forecast, by End-user (2017-2030)

11.2.5. Germany

11.2.5.1. Market Revenue and Forecast, by Disease Type (2017-2030)

11.2.5.2. Market Revenue and Forecast, by Treatment (2017-2030)

11.2.5.3. Market Revenue and Forecast, by End-user (2017-2030)

11.2.6. France

11.2.6.1. Market Revenue and Forecast, by Disease Type (2017-2030)

11.2.6.2. Market Revenue and Forecast, by Treatment (2017-2030)

11.2.6.3. Market Revenue and Forecast, by End-user (2017-2030)

11.2.7. Rest of Europe

11.2.7.1. Market Revenue and Forecast, by Disease Type (2017-2030)

11.2.7.2. Market Revenue and Forecast, by Treatment (2017-2030)

11.2.7.3. Market Revenue and Forecast, by End-user (2017-2030)

11.3. APAC

11.3.1. Market Revenue and Forecast, by Disease Type (2017-2030)

11.3.2. Market Revenue and Forecast, by Treatment (2017-2030)

11.3.3. Market Revenue and Forecast, by End-user (2017-2030)

11.3.4. India

11.3.4.1. Market Revenue and Forecast, by Disease Type (2017-2030)

11.3.4.2. Market Revenue and Forecast, by Treatment (2017-2030)

11.3.4.3. Market Revenue and Forecast, by End-user (2017-2030)

11.3.5. China

11.3.5.1. Market Revenue and Forecast, by Disease Type (2017-2030)

11.3.5.2. Market Revenue and Forecast, by Treatment (2017-2030)

11.3.5.3. Market Revenue and Forecast, by End-user (2017-2030)

11.3.6. Japan

11.3.6.1. Market Revenue and Forecast, by Disease Type (2017-2030)

11.3.6.2. Market Revenue and Forecast, by Treatment (2017-2030)

11.3.6.3. Market Revenue and Forecast, by End-user (2017-2030)

11.3.7. Rest of APAC

11.3.7.1. Market Revenue and Forecast, by Disease Type (2017-2030)

11.3.7.2. Market Revenue and Forecast, by Treatment (2017-2030)

11.3.7.3. Market Revenue and Forecast, by End-user (2017-2030)

11.4. MEA

11.4.1. Market Revenue and Forecast, by Disease Type (2017-2030)

11.4.2. Market Revenue and Forecast, by Treatment (2017-2030)

11.4.3. Market Revenue and Forecast, by End-user (2017-2030)

11.4.4. GCC

11.4.4.1. Market Revenue and Forecast, by Disease Type (2017-2030)

11.4.4.2. Market Revenue and Forecast, by Treatment (2017-2030)

11.4.4.3. Market Revenue and Forecast, by End-user (2017-2030)

11.4.5. North Africa

11.4.5.1. Market Revenue and Forecast, by Disease Type (2017-2030)

11.4.5.2. Market Revenue and Forecast, by Treatment (2017-2030)

11.4.5.3. Market Revenue and Forecast, by End-user (2017-2030)

11.4.6. South Africa

11.4.6.1. Market Revenue and Forecast, by Disease Type (2017-2030)

11.4.6.2. Market Revenue and Forecast, by Treatment (2017-2030)

11.4.6.3. Market Revenue and Forecast, by End-user (2017-2030)

11.4.7. Rest of MEA

11.4.7.1. Market Revenue and Forecast, by Disease Type (2017-2030)

11.4.7.2. Market Revenue and Forecast, by Treatment (2017-2030)

11.4.7.3. Market Revenue and Forecast, by End-user (2017-2030)

11.5. Latin America

11.5.1. Market Revenue and Forecast, by Disease Type (2017-2030)

11.5.2. Market Revenue and Forecast, by Treatment (2017-2030)

11.5.3. Market Revenue and Forecast, by End-user (2017-2030)

11.5.4. Brazil

11.5.4.1. Market Revenue and Forecast, by Disease Type (2017-2030)

11.5.4.2. Market Revenue and Forecast, by Treatment (2017-2030)

11.5.4.3. Market Revenue and Forecast, by End-user (2017-2030)

11.5.5. Rest of LATAM

11.5.5.1. Market Revenue and Forecast, by Disease Type (2017-2030)

11.5.5.2. Market Revenue and Forecast, by Treatment (2017-2030)

11.5.5.3. Market Revenue and Forecast, by End-user (2017-2030)

Chapter 12. Company Profiles

12.1. Novartis AG

12.1.1. Company Overview

12.1.2. Product Offerings

12.1.3. Financial Performance

12.1.4. Recent Initiatives

12.2. Bosch Healthcare Solutions GmbH

12.2.1. Company Overview

12.2.2. Product Offerings

12.2.3. Financial Performance

12.2.4. Recent Initiatives

12.3. Bayer AG

12.3.1. Company Overview

12.3.2. Product Offerings

12.3.3. Financial Performance

12.3.4. Recent Initiatives

12.4. F. Hoffmann-La Roche Ltd

12.4.1. Company Overview

12.4.2. Product Offerings

12.4.3. Financial Performance

12.4.4. Recent Initiatives

12.5. Regeneron Pharmaceuticals Inc.

12.5.1. Company Overview

12.5.2. Product Offerings

12.5.3. Financial Performance

12.5.4. Recent Initiatives

12.6. AbbVie Inc.

12.6.1. Company Overview

12.6.2. Product Offerings

12.6.3. Financial Performance

12.6.4. Recent Initiatives

12.7. Teva Pharmaceutical Industries Ltd.

12.7.1. Company Overview

12.7.2. Product Offerings

12.7.3. Financial Performance

12.7.4. Recent Initiatives

12.8. Samsung Bioepis

12.8.1. Company Overview

12.8.2. Product Offerings

12.8.3. Financial Performance

12.8.4. Recent Initiatives

Chapter 13. Research Methodology

13.1. Primary Research

13.2. Secondary Research

13.3. Assumptions

Chapter 14. Appendix

14.1. About Us

14.2. Glossary of Terms